AutoKinetics high dosing group (36) | AutoKinetics low dosing group (24) | AutoKinetics Normal dosing group (72) | Control (120) | p value (adjusted)a | |
---|---|---|---|---|---|
ICU mortality, n (%) | 11 (30.6) | 7 (29.2) | 27 (37.5) | 44 (36.7) | 0.801 (0.998) |
Hospital mortality, n (%) | 11 (30.6) | 9 (37.5) | 27 (37.5) | 47 (39.2) | 0.667 (0.997) |
28-day mortality, n (%) | 11 (30.6) | 7 (29.2) | 27 (37.5) | 48 (40.0) | 06.27 (0.997) |
6-month mortality, n (%) | 13 (36.1) | 10 (41.7) | 33 (45.8) | 59 (49.2) | 0.557 (0.997) |
New onset AKI, n (%) | 16 (44.4) | 3 (12.5) | 25 (34.7) | 50 (41.7) | 0.041 (0.416) |
Highest KDIGO stage, n (%) | 0.119 (0.752) | ||||
0 | 10 (27.8) | 5 (20.8) | 15 (20.8) | 15 (12.5) | |
1 | 4 (11.1) | 3 (5.6) | 4 (5.6) | 19 (15.8) | |
2 | 16 (44.4) | 6 (25.0) | 25 (34.7) | 44 (36.7) | |
3 | 6 (16.7) | 10 (41.7) | 28 (38.9) | 42 (35.0) | |
Received CVVH, n (%) | 2 (5.6) | 5 (20.8) | 11 (15.3) | 19 (15.8) | 0.352 (0.980) |
Days free from CVVH, median (IQR) | 3.0 (2.0 to 9.2) | 3.0 (1.0 to 10.5) | 4.5 (2.0 to 10.0) | 4.0 (2.0 to 10.0) | 0.795 (0.998) |
SOFA score at 96 h, median (IQR) | 9.0 (5.0 to 12.2) | 13.5 (10.0 to 24.0) | 9.0 (5.8 to 14.2) | 10.0 (5.9 to 19.2) | 0.075 (0.607) |
Delta SOFA score at 96 h, median (IQR) | − 1.0 (− 3.0 to 4.0) | 0.0 (− 1.5 to 4.0) | 0.0 (− 3.0 to 3.2) | 0.0 (− 2.0 to 4.0) | 0.523 (0.997) |
Hospital LOS, median (IQR) | 12.7 (5.4 to 26.5) | 29.3 (1.1 to 37.4) | 14.0 (6.5 to 29.3) | 12.2 (3.4 to 28.4) | 0.828 (0.998) |
ICU LOS, median (IQR) | 2.3 (1.8 to 7.0) | 3.5 (1.1 to 11.2) | 4.2 (1.6 to 11.7) | 3.6 (1.0 to 11.0) | 0.792 (0.998) |
Coadministered study antibiotic, n (%) | |||||
Vancomycin | 6 (17.6) | 4 (15.4) | 19 (26.4) | 26 (21.7) | |
Ciprofloxacin | 4 (11.8) | 10 (38.5) | 19 (26.4) | 38 (31.7) | |
Meropenem | 2 (5.9) | 2 (7.7) | 9 (12.5) | 5 (4.2) | |
Ceftriaxone | 12 (35.3) | 2 (7.7) | 17 (23.6) | 28 (23.3) |